Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer
PredicineCARE™ was applied for ultra-deep targeted sequencing and somatic alteration identification in tumor DNA (tDNA), urinary tumor DNA (utDNA), and circulating tumor DNA (ctDNA) in a UBC patient cohort and concordance was evaluated.
Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients
Using PredicineATLAS™ to analyze somatic mutations and copy number changes in PI3K/AKT pathway, NOTCH signaling pathway, hedgehog signaling pathway and pathways involved in DNA damage repair might be potential mechanisms underlying TKI resistance.
Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing
Using PredicineCARE™ to analyze TP53 mutations in cell-free DNA from patients with metastatic breast cancer to investigate disease characteristics and the prognostic role of different locations of the TP53 mutation site.
Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer
PTEN-PI3K-AKT pathway CNVs were detected using Predicine’s cfDNA liquid biopsy assay, with the prevalence of PTEN loss comparable with tissue-based studies. Plasma cfDNA profiling may facilitate and optimize patient selection for targeted treatment with Akt inhibitors in mCRPC.
Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?
An editorial to introduce an upcoming study that leverages Predicine’s next-gen liquid biopsy technology to investigate plasma cfDNA- and cfRNA-based AR molecular profiling in metastatic castration-resistant prostate cancer.
Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
•Predictive value of germline ATM mutations in mPDAC patients receiving PD-L1 + CTLA4 combo immunotherapies, demonstrating the value of the PredicineATLAS test in both blood TMB profiling and germline profiling to identify patient subgroups who may benefit from immunotherapy.
Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
• PredicineATLAS™ to assess the predictive value of plasma TMB in mPDAC
Next generation sequencing-based gene variant-oriented characterization in metastatic breast cancer: An innovative analysis using ctDNA
Lorenzo Gerratana, Qiang Zhang, Ami N Shah, Alessandra Franzoni, Jianjun Yu, Shidong Jia, Andrew A Davis, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradishar and Massimo Cristofanilli
Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and metastatic castration resistant prostate cancer (mCRPC) states and their impact on survival
Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee